Palliative Radiation Therapy for Oncologic Emergencies in the Setting of COVID-19: Approaches to Balancing Risks and Benefits.


Journal

Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247

Informations de publication

Date de publication:
Historique:
received: 29 03 2020
revised: 31 03 2020
accepted: 01 04 2020
pubmed: 5 5 2020
medline: 5 5 2020
entrez: 5 5 2020
Statut: epublish

Résumé

Palliation of metastatic disease compromises a significant portion of radiation treatments in the United States. These patients present a unique challenge in resource-limited settings, as expeditious treatment is often required to prevent serious morbidity. In order to reduce the risk of infection with severe acute respiratory syndrome coronavirus-2 and maximize the benefit to patients, we present evidence-based recommendations for radiation in patients with oncologic emergencies. Radiation oncologists with expertise in the treatment of metastatic disease at a high-volume comprehensive cancer center reviewed the available evidence and recommended best practices for the treatment of common oncologic emergencies, with attention to balancing the risk of infection with severe acute respiratory syndrome coronavirus-2 and the potential morbidity of delaying treatment. Many prospective trials and national guidelines support the use of abbreviated courses of radiotherapy for patients with oncologic emergencies. As such, in the setting of the current coronavirus disease 2019 pandemic, the use of hypofractionated radiation therapy for patients requiring palliation for oncologic emergencies achieves desirable functional outcomes without compromising care.

Identifiants

pubmed: 32363243
doi: 10.1016/j.adro.2020.04.001
pii: S2452-1094(20)30069-5
pmc: PMC7194647
doi:

Types de publication

Journal Article

Langues

eng

Pagination

589-594

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2020 The Author(s).

Références

Acta Oncol. 2018 Jul;57(7):965-972
pubmed: 29419331
J Natl Cancer Inst. 2005 Jun 1;97(11):798-804
pubmed: 15928300
Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):399-403
pubmed: 7679668
Adv Radiat Oncol. 2020 Apr 01;5(4):659-665
pubmed: 32292839
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
J Clin Oncol. 2011 Jun 10;29(17):2319-26
pubmed: 21555700
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Radiother Oncol. 2009 Nov;93(2):174-9
pubmed: 19520448
Ann Palliat Med. 2019 Sep;8(4):356-359
pubmed: 31431024
Cancer. 2014 Jan 1;120(1):134-41
pubmed: 24122413
Oral Oncol. 2015 Oct;51(10):957-62
pubmed: 26282714
Clin Infect Dis. 2010 Sep 15;51 Suppl 2:S224-30
pubmed: 20731581
J Clin Oncol. 2004 Mar 1;22(5):801-10
pubmed: 14990635
Strahlenther Onkol. 2008 May;184(5):251-5
pubmed: 18427755
J Clin Oncol. 2005 May 20;23(15):3366-75
pubmed: 15908648
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Radiother Oncol. 2019 May;134:55-66
pubmed: 31005225
BMC Palliat Care. 2011 Aug 09;10:13
pubmed: 21827696
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):462-467
pubmed: 29726364
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1291-302
pubmed: 12128132
Int J Radiat Oncol Biol Phys. 1981 Dec;7(12):1633-8
pubmed: 6174490
Strahlenther Onkol. 2011 Nov;187(11):729-35
pubmed: 22037654
Neuro Oncol. 2013 Oct;15(10):1429-37
pubmed: 23956241
J Clin Oncol. 2016 Feb 20;34(6):597-602
pubmed: 26729431
Pract Radiat Oncol. 2014 Nov-Dec;4(6):349-55
pubmed: 25407853
JAMA Oncol. 2019 Jun 1;5(6):872-878
pubmed: 31021390
J Clin Oncol. 2004 Sep 1;22(17):3581-6
pubmed: 15337808
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Lancet. 2016 Oct 22;388(10055):2004-2014
pubmed: 27604504
JAMA. 2019 Dec 3;322(21):2084-2094
pubmed: 31794625
Br J Cancer. 2005 Mar 28;92(6):1038-45
pubmed: 15770205
J Natl Compr Canc Netw. 2019 Aug 1;17(8):977-1007
pubmed: 31390582
Adv Radiat Oncol. 2020 Apr 01;5(4):582-588
pubmed: 32292842
Pract Radiat Oncol. 2014 Mar-Apr;4(2):76-81
pubmed: 24890347
Oncologist. 2013 Jun;18(6):744-51
pubmed: 23709750
Int J Radiat Oncol Biol Phys. 1987 Oct;13(10):1479-82
pubmed: 2442127

Auteurs

Divya Yerramilli (D)

PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Amy J Xu (AJ)

PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Erin F Gillespie (EF)

PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Annemarie F Shepherd (AF)

PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Kathryn Beal (K)

PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Daniel Gomez (D)

PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Josh Yamada (J)

PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

C Jillian Tsai (CJ)

PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

T Jonathan Yang (TJ)

PROMISE (Precision Radiation for Oligometastatic and Metastatic Disease) Program, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.

Classifications MeSH